Understanding the implications of co-delivering therapeutic agents in a nanocarrier to combat multidrug resistance (MDR) in breast cancer

Cancer is one of the leading causes of death worldwide. Breast cancer is the most prevalent cancer amongst women which can be treated by chemotherapy. During chemotherapy, some chemotherapeutic drugs fail to show action as the cancerous cells develop resistance against the drugs thereby causing multidrug resistance (MDR) in the body. Different treatment choices are available for the MDR. However, understanding the implications of co delivering therapeutic agents in a nanocarrier to treat MDR cancer gives the treatment a new perspective. Nanocarriers like liposomes, polymeric micelles, metallic nanoparticles, or dendrimers all contribute in co delivering different chemotherapeutics. The article reviews the principle mechanisms, and factors leading to overcome resistance in breast cancer.

Automated summary

Cancer is a leading cause of death worldwide, with breast cancer being the most common cancer among women. Chemotherapy may face challenges due to multidrug resistance in cancerous cells, but co-delivering therapeutic agents in nanocarriers offers a new perspective for treatment. Various types of nanocarriers can contribute to delivering different chemotherapeutics to overcome resistance in breast cancer.